{"entity":{"id":"duboce-biopharmaceuticals","kind":"company","name":"Duboce Biopharmaceuticals","aka":["Duboce Biopharmaceuticals, Inc."],"tldr":"Duboce Biopharmaceuticals is developing DBC-664, an antibody that links the immune system's T cells to cancer cells carrying the proteins ALPP or ALPPL2, which are common in ovarian and endometrial cancers. It is in a first human trial.","summary":"Duboce Biopharmaceuticals, Inc. is a single-asset portfolio company of TCG Labs Soleil, the South San Francisco venture-biotech organisation formed with The Column Group. Its candidate DBC-664 is an ALPP/ALPPL2 x CD3 T-cell engager directed at antigens highly expressed, most homogeneously, in ovarian and endometrial cancers. A first-in-human, open-label, multicentre phase 1a/1b study (NCT07705035) in adults with relapsed or refractory, unresectable locally advanced or metastatic solid tumours associated with ALPP or ALPPL2 expression, including germ cell tumours, lung, gastric and oesophageal, urothelial, endometrial and ovarian adenocarcinomas, began recruiting in 2026. Its first registered cancer trial, NCT07705035, was posted on ClinicalTrials.gov in July 2026.","asOf":"2026-10-29","links":[{"label":"TCG Labs Soleil release on portfolio programmes in first-in-human trials, 28 October 2026","url":"https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/"},{"label":"ClinicalTrials.gov: phase 1a/1b trial of DBC-664 (NCT07705035)","url":"https://clinicaltrials.gov/study/NCT07705035"}],"tags":[],"related":[],"cancers":["ovarian","endometrial","lung-adenocarcinoma","urothelial"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No company website was found; the registry contact domain is tcglsoleil.com, the parent organisation's. Facts come from the TCG Labs Soleil release of 28 October 2026 and the ClinicalTrials.gov record NCT07705035, both read on 29 October 2026. HQ is the parent's address.","Founding year and financing for Duboce itself were not stated. TCG Labs Soleil is not an OnCo record. No ALPP or ALPPL2 target record exists in OnCo."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","stage":"startup","investors":[],"funding":[]},"route":"/companies/duboce-biopharmaceuticals/","neighbours":{"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}]}}